Rationale for the management of coronary syndromes with low-molecular- weight heparins

American Journal of Cardiology

Volumn 82, Issue 5 B, 1998, Pages 15L-18L

  Gurfinkel, Enrique ^a   Fareed, Jawed ^b   Antman, Elliot ^b   Cohen, Marc ^b   Mautner, Branco ^b  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032505112     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00107-6     Document Type: Conference Paper

References (37)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-808.
2. Gerrity RG. The role of the monocyte in atherogenesis. Am J Pathol 1981; 103:181-190.
3. Mazzone A, De Servi S, Ricvutti G, Mazzuccelli I, Fossati G, Pasotti D, Bramucci E, Angoli L, Marsico F, Secchi G, Notario A. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993;88:358-360.
4. van der Wal AC, Becker A, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;90:1662-1668.
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of the coronary artery disease and the acute coronary syndromes: Part 1 and 2. N Engl J Med 1992;326:242-318.
6. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable artery disease. N Engl J Med 1987;317:1361-1365.
7. Theroux P, Latour JG, Leger-Gautier C, De Lara J. Fibrinopeptide A plasma levels and platelet factor 4 levels in unstable angina pectoris. Circulation 1987; 75:156-162.
8. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation 1985;71: 912-918.
9. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/prothrombin fragment 1+2 thrombin/antithrombin complex. Blood 1982;59:1086-1097.
10. Gurfinkel E, Altman R, Rouvier J, Scazziota A, Mautner B. Significance of thrombosis and thrombolysis in silent myocardial ischemia. Br Heart J 1994;71: 151-155.
11. Krucoff MW, Wagner NB, Pope JE, Morata DM, Jackson YR, Bottner RK, Wagner GS, Kent KS. The portable programmable microprocessor-driven real-time 12-lead electrocardiographic monitor: preliminary report of a new device for the non invasive detection of successful reperfusion or silent coronary reocclusion. Am J Cardiol 1990;65:143-148.
12. Gurfinkel E, Bozovich G, Mejaíl I, Cerdá M, Oxilia A, Mautner B. Time significance of acute thrombotic reactant markers in patients with and without silent myocardial ischemia and overt unstable angina. Am J Cardiol 1995;76: 121-124.
13. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley KM, Edwards C, Green LA, Mushlin AI, Swain JA, Smith III EE, Cowan M, Rose GC, Concannon CA, Grines CL, Brown L, Lytle BW, Goldman L, Topol EJ, Willerson JT, Brown J, Archibald N. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline No 10. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung and Blood Institute, Public Health Service. US Department of Health and Human Services, 1994:154.
14. Lewis HDJ, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3d, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-399.
15. Theroux P, Waters D, Qiu S, McCans J, De Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88:2045-2049.
16. Wallentin L, RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.
17. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996;276;811-815.
18. Theroux P, Quimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, De Guise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-1111.
19. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V. Combination antithrombotic therapy in unstable rest angina and non Q-wave infarction in non prior aspirin users. Circulation 1994;89:81-88.
20. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a standard care nomogram. Ann Intern Med 1993;119:874-877.
21. Gurfinkel E, Manos E, Mejaíl I, Duronto E, Cerda M, Daroca A, Garcia N, Mautner B. Regular heparin use in a trial of unstable angina nomogram of infusion and aPTT target time in relation to major bleeding. Thromb Haemostas 1995;73(suppl):981.
22. The TIMI 3B Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Circulation 1994;89:1545-1556.
23. Theroux P, Waters DD, Lam J, Junmau M, McCanse J. Reactivation of unstable angina following discontinuation of heparin. N Engl J Med 1992;327: 141-145.
24. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf RM. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935.
25. Sylvén C, Hagerman I, Karlberg KE, Chen J, Wallin R, Eneroth P, Bergström K, Saldeen T. Platelet and leukocyte activation after myocardial infarction. Eur Heart J 1995;16:1800-1806.
26. Salzman EW. Low molecular weight heparin: is small beautiful? N Engl J Med 1986;315:957-959.
27. Hirsh J. Low molecular weight heparin. Thromb Haemostas 1993;70:204-207.
28. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of acute unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-318.
29. Cairns JA, Hirsh J, Lewis HD, Resnekov L, Theroux P. Antithrombotic agents in coronary artery disease. Chest 1992;102:456S-481S.
30. Cohen M, Turpie AGG, Demers C, Gurfinkel, E Fromell G, Langer A, Goodman S, Califf R, Fox K, Premmereur J, Bigonzi F for the ESSENCE Group. Blind comparison of enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary artery disease: the ESSENCE Trial. Thromb Haemost 1997;(suppl)374.
31. Ariens RAS, Faioni EM, Mannucci PM. Repeated release of the tissue factor pathway inhibitor. Thromb Haemostas 1984;72:327-378.
32. Carr C, Bild GS, Chang ACK, Peer GT, Palmier MO, Frazier RB, Gustafson ME, Wun T-C, Creasey AA, Hinshaw LB, Taylor Jr FB, Galluppi GR. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1995;44:126-137.
33. Creasey AA, Chang ACK, Feigen L, Wun T-C, Taylor Jr FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2860.
34. Gikakis N, Khan M, Hiramatsu Y, Gormant III JH, Hack C, Sun L, Rao AK, Niewirowski S, Colman R, Samunds JRH. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during extracorporeal circulation. Circulation 1996;94(suppl 2):II-341-II-346.
35. Gurfinkel E, Bozovich G, Pombo G, Puente D, Cohen M, Mauther B. Acute thrombotic reactant markers in patients with non Q wave coronary events treated with either enoxaparin or unfractionated heparin. Thromb Haemostas 1997; (suppl)286.
36. The FRISC Study Group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996;561-568.
37. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation, 1997;96:61-8.